Home Infusion Platforms: CVS Coram vs Option Care Health vs Naven Health
Head-to-head comparison of the three dominant home and alternate-site infusion models biotech commercialization teams evaluate when planning IV/SC biologic launches.
Curated by Rx Almanac using company materials, public reporting, and editorial synthesis.
On this page
Save this comparison — email yourself the full breakdown.
Join 200+ biotech launch teams on the weekly digest.
- Big-3 Specialty Pharmacy: CVS Specialty vs Accredo vs OptumRx Specialty — related bundled-infusion analysis
Market Position Summary
The U.S. home infusion market reached approximately $25.99B in 2025 (Mordor Intelligence), within a total U.S. infusion therapy market of ~$100B (home + ambulatory suites + HOPD). The market is highly fragmented with the top 3 home infusion providers commanding ~35–40% combined share. Following CVS Coram’s October 2024 acute-infusion exit, Option Care Health is the unambiguous #1 by revenue at $5.65B. CVS Coram’s restructuring narrowed its footprint to specialty biologics + TPN + enteral nutrition.
| Attribute | CVS Coram | Option Care Health | Naven Health |
|---|---|---|---|
| Business Model | PBM-owned specialty home infusion | Independent integrated home infusion (pharmacy + suite + nursing) | Nursing network only (white-label for pharma) |
| Parent Company | CVS Health (NYSE: CVS) | Publicly traded (NASDAQ: OPCH) | Option Care Health (NASDAQ: OPCH) |
| 2025 Revenue (est.) | ~$1.5–2.5B (post-restructuring; not disclosed) | $5.65B (FY2025, +13% YoY) | Not separately disclosed (Option Care subsidiary) |
| 2024 Market Share (Home Infusion) | Pre-exit ~15%; post-exit ~8–10% | ~25% home infusion | N/A (nursing only) |
| Locations | 3 national hub pharmacies + Coram AIS (select CVS retail) | 197+ locations + 750+ infusion suite chairs | 1,600+ community-based nurses (no physical locations) |
| State Coverage | National (via 3 hubs) | 50-state licensure | 50-state nurse deployment |
| Annual Patients | ~20,000/month (~240,000+ annual) | 315,000+ | 160,000+ patient visits |
| Annual Infusion Events | Not disclosed | 2.5M+ | N/A |
| Nursing Network | Via Coram + CVS clinical staff | Naven Health (subsidiary, 1,600+ nurses) | 1,600+ nurses direct |
| Accreditation | TJC (The Joint Commission) — only national home infusion with this | URAC Specialty Pharmacy | Joint Commission |
| Infusion Suites | Coram Ambulatory Infusion Suites (AIS) in select CVS retail; count reduced post-restructuring | 750+ infusion chairs across 197+ locations | N/A (nurses deploy to home or partner sites) |
| Biotech Buyer Profile | Best for specialty biologic + IVIg manufacturers seeking bundled CVS Specialty + CVS Caremark access | Best for national launches needing pharmacy + suite + nursing in one contract | Best for manufacturers self-managing distribution/SP and needing only nursing |
Vertical Integration & Distribution Stack
The three vendors sit in very different strategic positions. CVS Coram is a node in CVS Health’s ~$473B vertically integrated insurance+PBM+SP+retail stack. Option Care Health is a pure-play integrated infusion independent. Naven Health is a nursing-only subsidiary that Option Care offers as a white-label product to pharma manufacturers.
| Layer | CVS Coram | Option Care Health | Naven Health |
|---|---|---|---|
| Parent | CVS Health (~$473B gross) | Independent public (OPCH) | Option Care Health |
| Insurance Sister | Aetna (~25M+ members) | None | None |
| PBM Sister | CVS Caremark (~87M lives) | None | None |
| Specialty Pharmacy Sister | CVS Specialty (~$75–80B, #1 SP) | Limited self-operated SP | None |
| Retail Pharmacy Sister | 9,000 CVS retail (co-location for AIS) | None | None |
| Care Mgmt Sister | Accordant Health Services (20 rare conditions) | None | None |
| Field Services Sister | Signify Health, Oak Street Health | None | None |
| Revenue Model | Fee-for-service infusion; bundled contracts with CVS Specialty/Caremark common | Fee-for-service infusion; direct manufacturer/payer contracts | Per-visit nursing fees; white-label patient support program fees to pharma |
| Captive Patient Channeling | CVS Caremark specialty Rx → CVS Specialty dispensing → Coram administration | None — accesses patients via manufacturer referrals, health systems, and direct payer contracts | None — manufacturers hire Naven for nursing services on their patient population |
Implication for manufacturers: Choosing Coram is rarely just choosing an infusion vendor — it typically comes as part of a CVS Specialty + CVS Caremark + (sometimes Aetna) bundled specialty access package. Choosing Option Care Health is selecting an independent pharmacy-infusion-nursing platform. Choosing Naven alone (decoupled from Option Care’s pharmacy) is selecting nursing only, typically when the manufacturer is using a different specialty pharmacy or managing its own distribution.
Therapy Mix & Site-of-Care Economics
Each vendor has different therapeutic strengths reflecting its post-restructuring strategic focus (Coram), scale footprint (Option Care), or clinical specialization (Naven).
| Therapy Area | CVS Coram | Option Care Health | Naven Health |
|---|---|---|---|
| Immunoglobulin (IVIg/SCIg) | Core therapeutic anchor (primary volume) | 80,000+ IVIg treatments annually (largest single category) | High-volume Ig nursing via Option Care Rx |
| Autoimmune / Inflammatory Biologics | Infliximab, vedolizumab, other IV biologics | Infliximab, vedolizumab, other biologics; largest infusion site volumes | Home-based autoimmune infusion; 350+ therapies |
| Oncology Infusion | Coordinated with CVS Specialty (limited direct oncology IV) | Growing — biosimilar-driven volume; IV chemotherapy, immunotherapy | Limited oncology (PD-1 select therapies); most oncology remains HOPD |
| Rare Disease / ERT | Select orphan biologics; coordinated with CVS Specialty | Enzyme replacement therapies, complement inhibitors | Rare/orphan biologic nursing |
| Anti-infectives / OPAT | ❌ Exited October 2024 | IV antibiotics, OPAT (high volume, shorter duration) | IV antibiotic nursing available |
| TPN / Parenteral Nutrition | Core retained service — one of largest national TPN providers | TPN available | Nursing support only |
| Enteral Nutrition | Core retained service | Available | Available |
| Hydration Therapy | ❌ Exited October 2024 | Available | Available |
| Alpha-1 Antitrypsin | Core retained service | Available | Available |
| Hemophilia / Factor Replacement | Coordinated with CVS Specialty | Standard coverage | Available |
| Cell & Gene Therapy Admin | Coordinated with CVS Specialty CGT Experience Center | Emerging CGT administration capability | Limited CGT; most CGT in AMC/hospital setting |
| Site-of-Care Options | Home + Coram AIS (CVS retail co-located) | Home + 750+ suite chairs + alternate site | Home only (nursing deploys to home or partner sites) |
| Biosimilar Infusion | Active in CVS Caremark formulary-steered biosimilar channeling | Stelara biosimilar -160bps headwind near-term; long-term volume tailwind | Nursing-only, agnostic to pharmacy source |
Site-of-Care Economics
Cost comparison per infusion event (illustrative 2025):
- Hospital Outpatient Department (HOPD): $3,500–$8,000+ (varies by drug)
- Ambulatory Infusion Center / Suite: $1,500–$3,500
- Home infusion (nurse-administered): $1,700–$3,500
- Home infusion (self-administered SCIg): $500–$1,500
Implication: All three vendors operate in the lower-cost home/suite setting vs HOPD. Option Care’s 750+ suite chairs enable ambulatory infusion at scale, a meaningful advantage for patients who need clinical supervision but not home-based administration. CVS Coram’s AIS in CVS retail offers a similar alternate-site option at smaller scale post-restructuring. Naven is home-only (no suites).
Payer Contracting & Manufacturer Commercialization
The three vendors differ sharply in payer-relationship depth, manufacturer partnership models, and biotech suitability by launch stage.
| Dimension | CVS Coram | Option Care Health | Naven Health |
|---|---|---|---|
| Payer Contracting Depth | In-network for Aetna + CVS Caremark + most national commercial/Medicare Advantage | National contracts with all major commercial payers, Medicare Advantage, and PBMs | Contracts via Option Care parent + direct manufacturer contracts |
| PBM Channeling | Strong (captive via Caremark’s ~87M lives) | None (independent, channel-neutral) | None |
| Medicare Advantage Positioning | Preferred within Aetna + CVS Caremark MA formularies | Preferred across MA plans (CMS Stars quality tailwind) | N/A (nursing doesn’t contract directly with payers for drug reimbursement) |
| Manufacturer Partnership Model | Bundled with CVS Specialty SP; manufacturer typically negotiates PBM + SP + infusion together | Direct SP-infusion contracts or standalone infusion administration contracts | White-label nurse staffing for manufacturer-funded patient support programs |
| Patient Support Program Capability | Via CVS Specialty hub integration | Full PSP + adherence + reporting via Option Care clinical team | Dedicated pharma PSP services; 130+ pharma/SP partners |
| Launch Scale-Up Speed | Moderate (via 3 hubs) | Fast (197+ locations, 50-state licensure) | Very fast (24–48 hour nurse deployment in all 50 states) |
| Data Reporting to Manufacturer | Limited direct-to-manufacturer visibility (Caremark/CVS Specialty intermediation) | Real-time infusion event data, adherence, abandonment via manufacturer dashboards | Detailed patient visit data, adherence tracking, adverse events via Naven Connect (AlayaCare) |
| Biosimilar Channeling Risk | High — CVS Caremark formulary steerage affects Coram patient population | Moderate — Option Care channel-neutral but subject to PBM mandates | Low — nursing-only, drug source-agnostic |
Biotech Buyer Best-For Recommendations
Best for CVS Coram:
- Immunoglobulin manufacturers (IVIg/SCIg) where CVS Specialty is a major LDD SP
- Autoimmune biologic manufacturers seeking bundled CVS Specialty + Coram access
- Alpha-1 antitrypsin manufacturers (concentrated therapeutic area)
- TPN and parenteral nutrition manufacturers
- Brands with heavy CVS Caremark + Aetna member concentration
- Manufacturers prioritizing TJC accreditation for quality-sensitive therapies
Best for Option Care Health:
- National launches requiring pharmacy + suite + nursing in a single integrated contract
- Biologic manufacturers needing broad site-of-care flexibility (home, suite, alternate site)
- Oncology infusion (growing biosimilar volume)
- Manufacturers seeking deep real-time data reporting across infusion events
- Brands where PBM-channel-neutrality is strategically important (avoiding captive steerage)
- Manufacturers requiring 50-state coverage with 750+ infusion suite chairs
Best for Naven Health (standalone, independent of Option Care pharmacy):
- Manufacturers using a different specialty pharmacy (not Option Care, CVS Specialty, or a Big-3 SP) and needing nursing as a separate service
- Direct-to-consumer pharma models requiring white-label nursing
- Clinical trial sponsors needing decentralized trial nurse support
- Rare disease manufacturers requiring rapid 24–48 hour nurse deployment in any U.S. location
- Manufacturers managing in-house patient support programs and needing nursing as a plug-in service
Better together (bundled):
- Option Care + Naven is the default integrated model (Naven is Option Care’s subsidiary)
- CVS Specialty + Coram is the default bundled PBM-owned specialty + infusion model
- Some biotechs use Option Care for infusion + CVS Specialty for dispensing (split model) when the therapy has overlapping SP and infusion requirements
Regulatory & Ownership Risk Comparison
The three vendors face materially different regulatory and ownership risks that biotech buyers should factor into multi-year contracts.
| Risk Type | CVS Coram | Option Care Health | Naven Health |
|---|---|---|---|
| PBM-Pharmacy Divestiture Legislation | High risk (Arkansas law effective Jan 2026; Patients Before Monopolies Act pending) — could force structural separation from CVS Caremark | None (independent) | None (not PBM-owned) |
| CMS Stars Quality Requirement | Strong positioning | Strong positioning (structural tailwind) | N/A (not quality-scored directly) |
| Parent Company Divestiture Risk | Moderate — CVS Health portfolio rationalization ongoing; Coram further exit not announced but speculated | Low — pure-play; Board committed to infusion | Tied to Option Care parent — low |
| Nursing Labor Shortage Exposure | High — cited as rationale for 2024 restructuring | High — industry-wide challenge | Highest — nursing is 100% of business model |
| Reimbursement Pressure | Moderate — captive PBM channeling provides some insulation | Moderate — CMS home infusion benefit stable; commercial reimbursement pressure | Moderate — nursing reimbursement varies by payer |
| Biosimilar Margin Compression | Moderate — CVS Caremark formulary steerage affects Coram dispensing margins | Moderate — Stelara biosimilar -160bps headwind; biosimilar volume tailwind long-term | Low — nursing margins less drug-tied |
RFP Buyer Checklist
When evaluating CVS Coram, Option Care Health, and Naven Health for a biotech IV biologic launch, biotech commercialization teams should pressure-test the following questions:
- Captive channel dependency: What percentage of your patient volume today comes from captive PBM/SP channels vs. independent payer contracts? (CVS Coram will have high Caremark captive share; Option Care will show broad payer mix; Naven shows manufacturer-contract concentration.)
- Post-restructuring Coram footprint: How many Ambulatory Infusion Suites (AIS) does Coram currently operate, and which MSAs? (Not publicly disclosed; ask directly.)
- Nursing network overlap: Does Option Care’s 1,600+ nurse footprint via Naven overlap with our manufacturer-contracted Naven nurses, and how is capacity prioritized when both are competing for the same patient? (Potential conflict — both are subsidiaries of Option Care.)
- CVS Caremark formulary steerage: If we’re launching a biosimilar or branded biologic with Caremark formulary coverage risk, how will Coram’s dispensing and administration be affected by formulary changes?
- Site-of-care flexibility: What percentage of your infusion events are home vs. suite vs. alternate site? (Option Care’s 750+ suite chairs vs. Coram’s AIS vs. Naven home-only determines site-of-care strategy.)
- Data reporting and manufacturer dashboards: What real-time infusion event, adherence, and abandonment data do you provide directly to manufacturers vs. via intermediaries (SP, PBM, payer)?
- TJC vs URAC accreditation: Is TJC accreditation material to our therapy class? (Relevant for immunoglobulin manufacturers; less relevant elsewhere.)
- Capacity surge during launch: Can you add X nurses and Y infusion chair capacity within 90 days of launch if volume exceeds forecast? (Critical for biologic launches with uncertain demand curves.)
- Medicare Advantage positioning: What is your in-network status across the top 5 MA plans, and how has CMS Stars Quality Rating affected patient redirection to your network?
- Sustainability of post-restructuring Coram operations: What is CVS Health’s commitment to Coram operations over the next 3–5 years? (Ask directly; not publicly disclosed. Coram divestiture speculation remains in industry press.)
Outlook (2026–2028)
CVS Coram: Expected to maintain focused specialty + nutrition positioning post-restructuring. Potential risks include further CVS Health portfolio rationalization (Coram divestiture speculation), PBM-pharmacy divestiture legislation forcing structural separation from CVS Caremark, and continued nursing labor shortage pressure. Upside: CVS Specialty Pharmacy bundled value proposition remains unique among Big-3 PBM-owned SPs.
Option Care Health: Expected to consolidate market share from CVS Coram’s acute-exit patients, Intramed Plus acquisition integration, and ongoing M&A. 2026 guidance of $5.8–6.0B revenue with Net Debt/EBITDA at 2.0x suggests balance sheet capacity for further consolidation. Key risks: PBM formulary steerage of biosimilar infusion volumes, nursing labor cost inflation, potential entry of Amazon Pharmacy or other disruptors into home infusion.
Naven Health: Expected to continue scaling the pharma patient support program (PSP) nursing business, now at 130+ partners and 350+ therapies. Continued differentiation on 24–48 hour nurse deployment in all 50 states. Risks: commoditization of basic nursing staffing, competition from APS Health and regional networks, and manufacturer decisions to in-source PSP nursing.
Methodology & Confidence
- Market sizing: Mordor Intelligence, Emergen Research, Access Market Intelligence, industry analyst consensus
- Revenue data: Option Care Health (FY2025 public filings), CVS Health Q4 2025 (Coram not separately disclosed; industry estimates used), Naven Health (not disclosed; Option Care subsidiary financials)
- Restructuring details: Reuters, Healthcare Dive, Access Market Intelligence, CVS Health corporate communications
- Confidence: High for restructuring facts and Option Care scale; Medium for post-restructuring Coram revenue estimates (not publicly disclosed); High for Naven operational metrics (Option Care press releases)
- Key data gap: CVS Health does not separately disclose Coram post-restructuring revenue. All post-2024 revenue estimates for Coram are industry analyst approximations.
Editorial Firewall Disclosure
This comparison is written by the Rx Almanac editorial team using publicly available sources. None of the vendors named (CVS Coram, Option Care Health, Naven Health) has sponsored, reviewed, or approved this content. Material public claims are cited inline where they need immediate context. Feedback and correction requests via the contact page; fact-based corrections are applied on verification, promotional edits are not accepted.
Related Wiki Vendors (Auto)
Auto-generated cross-references closing audit-surfaced link gaps. Vendors named in the prose above without inline links are listed here so the wiki graph is queryable.
- CVS Health
- URAC
Rx Almanac maintains a private source register for each article. Material public claims are cited inline; sourcing standards and correction policy are described in our methodology.
Related Articles
Analysis
340B TPA Comparison: Apexus vs Sentry Data Systems vs Macro Helix
Covered-entity 340B TPA comparison for Apexus, Sentry Data Systems, and Macro Helix, with manufacturer channel-risk implications.
Analysis
Cell and Gene Therapy Services Comparison: Orsini vs PANTHERx vs Onco360 vs Accredo vs CVS
This comparison supports a manufacturer-side CGT launch decision: which specialty-pharmacy and access partner can handle product-specific requirements around cryogenic handling, REMS, treatment-center coordination, payer access, hub orchestration, and long-term follow-up.
Analysis
Oncology Pharmacy Network Design: LDD Segmentation and Specialty Pharmacy Selection
This analysis gives manufacturer launch teams a practical oncology specialty pharmacy network design framework: when to use Onco360, when to include PBM-owned SPs, when health-system pharmacies matter, and when independent specialists or rare-disease pharmacies should be in the network.
Get more analysis like this
Weekly pharma vendor intel: new comparisons, market updates, and expert insights.
Found an inaccuracy? Tell us.
Suggest a correction